BME:GRFBiotechs
How Stronger 2025 Profitability At Grifols (BME:GRF) Has Changed Its Investment Story
Grifols, S.A. recently reported its full-year 2025 results, with sales rising to €7,524 million and net income reaching €402 million, lifting basic and diluted EPS from continuing operations to €0.59.
The earnings release highlighted stronger profitability alongside revenue growth, suggesting that improved operations and product mix, including plasma-derived therapies, are becoming increasingly important to the business profile.
We’ll now examine how this combination of higher revenue and...